Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement

NCT ID: NCT05388682

Last Updated: 2023-12-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-19

Study Completion Date

2042-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. Evaluate the effect of medical treatment and percutaneous transluminal pulmonary angioplasty on takayasu arteritis with pulmonary artery involvement
2. evaluate the efficacy of FAPI in predicting the activity and treatment efficacy of takayasu arteritis with pulmonary artery involvement

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

At baseline, FAPI and FDG are performed to evaluate the activity of takayasu arteritis with pulmonary artery involvement. FAPI is also used to predict the treatment efficacy and prognosis of takayasu arteritis with pulmonary artery involvement.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Takayasu Arteritis With Pulmonary Artery Involvement Percutaneous Transluminal Pulmonary Angioplasty PAH Targeted Medication

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Percutaneous transluminal pulmonary angioplasty, Takayasu Arteritis with Pulmonary Artery Involvement

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Percutaneous transluminal pulmonary angioplasty

Percutaneous transluminal pulmonary angioplasty

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients diagnosed with Takayasu arteries with pulmonary arteries involvement

Exclusion Criteria

* Patients had pulmonary artery stenosis arising from CTEPH, fibrosing mediastinitis and congenital pulmonary artery stenosis
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chinese Pulmonary Vascular Disease Research Group

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

zhihong Liu, doctor

Role: PRINCIPAL_INVESTIGATOR

Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, , China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Zhihong Liu, doctor

Role: CONTACT

Phone: 86-010-88396589

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Zhihong Liu, doctor

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TAPAI

Identifier Type: -

Identifier Source: org_study_id